Company intelligence / Profile preview

Arxx Therapeutics

Ownership: Private
Development stage: Other

Overview

Arxx Therapeutics has initiated a Phase 1 first-in-human trial of AX-202, a first-in-class anti-S100A4 monoclonal antibody targeting non-resolving tissue fibrosis. The trial is enrolling healthy volunteers and patients with mild to moderate psoriasis, with results expected in 2024. The company aims to develop AX-202 as a disease-modifying agent for systemic sclerosis and other rare fibrotic diseases.

Therapeutic areas: Rare DiseasesDermatologyRheumatology
Modalities: Monoclonal antibodies
Industry: Biotech

Partnerships

Cancer Research UK

Beyond the preview

Go deeper on Arxx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arxx Therapeutics.